Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Kursexplosion von 383 % seit November und massiver Solana-Outperformer!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40X9V | ISIN: US47100L3015 | Ticker-Symbol:
NASDAQ
21.01.25
17:05 Uhr
6,410 US-Dollar
0,000
0,00 %
1-Jahres-Chart
JANOVER INC Chart 1 Jahr
5-Tage-Chart
JANOVER INC 5-Tage-Chart
GlobeNewswire (Europe)
202 Leser
Artikel bewerten:
(1)

Janover Inc.: Janover Announces BTC (Bitcoin) Adoption

Finanznachrichten News

BOCA RATON, FL, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Janover Inc. (Nasdaq: JNVR) ("Janover" or the "Company"), an AI-enabled platform connecting the commercial real estate industry, today announced it aims to begin accepting payments in Bitcoin ("BTC") as well as Ethereum ("ETH") and Solana ("SOL") for select services, underscoring the company's commitment to innovation within evolving market trends. This decision aligns with the increasing support for digital assets on both a domestic policy level and within broader financial markets, as seen in notable corporate strategies to leverage certain cryptocurrencies for long-term value creation.

"At Janover, we remain focused on our core business. We do, however, recognize the broadening acceptance and significant future potential of digital currencies like Bitcoin," said the company's CEO. "We've seen how companies like MicroStrategy have successfully capitalized on Bitcoin's appreciation, and we believe there's an opportunity to participate in the market in a measured, responsible way."

Janover plans to incorporate select cryptocurrencies into its accepted forms of payment and is contemplating a treasury allocation plan into these assets. While continuing to prioritize responsible risk management, the company intends to offer clients greater flexibility in their transactions, continuing to facilitate lower friction and truly modern financial experiences for commercial real estate stakeholders across the ecosystem.

About Janover Inc.

Janover is an AI-enabled platform that connects the commercial real estate industry. The company serves over one million annual web users and 1,000+ lenders, including more than 10% of U.S. banks in America, providing debt capital markets services, real estate syndication software, data and AI licensing, and insurance brokerage solutions to entrepreneurial multifamily and commercial real estate owners, developers and professionals. Janover operates through its Debt, Equity, and Insurance divisions, focusing on delivering needed technology-first solutions to commercial real estate professionals. Additional information about the Company is available at: https://janover.co/.

To view the latest investor presentation, please visit https://ir.janover.co/.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," strategy," "future," "likely," "may,", "should," "will" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) the effect of and uncertainties related the ongoing volatility in interest rates; (ii) our ability to achieve and maintain profitability in the future; (iii) the impact on our business of the regulatory environment and complexities with compliance related to such environment; (iv) our ability to respond to general economic conditions; (v) our ability to manage our growth effectively and our expectations regarding the development and expansion of our business; (vi) our ability to access sources of capital, including debt financing and other sources of capital to finance operations and growth and other risks and uncertainties more fully in the section captioned "Risk Factors" in the Company's Registration Statement on Form S-1 related to the public offering (SEC File No. File No. 333-267907) and other reports we file with the SEC. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Company Contact:
Bruce S. Rosenbloom, CFO
Telephone: (561) 782-2788
Email: IR@janover.co


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.